Acute on chronic heart failure—Which variations on B‐type natriuretic peptide levels? (original) (raw)

Abstract

Natriuretic peptides are useful diagnostic and prognostic markers in patients presenting to the emergency department (ED) with acute shortness of breath. However, B‐type natriuretic peptide (BNP) level represents a single snapshot in time, while changes relative to a patient's baseline may be useful in risk stratification. We aimed to define the variation of BNP levels between chronic stable and acute decompensated heart failure (ADHF) that is associated with significant clinical outcomes.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (24)

  1. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-1133.
  2. Francis GS, Felker GM, Tang WH. A test in context: critical evalua- tion of natriuretic peptide testing in heart failure. J Am Coll Cardiol. 2016;67(3):330-337.
  3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart fail- ure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.
  4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Associa- tion Task Force on practice guidelines. Circulation. 2013;128(16):1810- 1852.
  5. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
  6. Nakata K, Komukai K, Yoshii Y, et al. The optimal cut-off value of plasma BNP to differentiate heart failure in the emergency department in Japanese patients with dyspnea. Intern Med. 2015;54(23):2975-2980.
  7. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-2368.
  8. Worster A, Bledsoe RD, Cleve P, Fernandes CM, Upadhye S, Eva K. Reassessing the methods of medical record review studies in emer- gency medicine research. Ann Emerg Med. 2005;45(4):448-451.
  9. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-869.
  10. Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
  11. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strateg. 2012;9(4):e131-e9.
  12. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibi- tion versus enalapril in heart failure. N Engl J Med. 2014;371(11):993- 1004.
  13. Yandrapalli S, Andries G, Biswas M, Khera S. Profile of sacubi- tril/valsartan in the treatment of heart failure: patient selection and perspectives. Vasc Health Risk Manag. 2017;13:369-382.
  14. Martindale JL, Wakai A, Collins SP, et al. Diagnosing acute heart failure in the emergency department: a systematic review and meta-analysis. Acad Emerg Med. 2016;23(3):223-242.
  15. Trinquart L, Ray P, Riou B, Teixeira A. Natriuretic peptide testing in EDs for managing acute dyspnea: a meta-analysis. Am J Emerg Med. 2011;29(7):757-767.
  16. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N- Terminal-pro-brain natriuretic peptide predicts outcome after hospi- tal discharge in heart failure patients. Circulation. 2004;110(15):2168- 2174.
  17. Eurlings LW, Sanders-van Wijk S, van Kraaij DJ, et al. Risk strat- ification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study. J Card Fail. 2014;20(12):881-890.
  18. McQuade CN, Mizus M, Wald JW, Goldberg L, Jessup M, Umscheid CA. Brain-type natriuretic peptide and amino-terminal pro-brain-type natriuretic peptide discharge thresholds for acute decompensated heart failure: a systematic review. Ann Intern Med. 2017;166(3):180- 190.
  19. Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19(4):507- 519.
  20. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90(3):254-258.
  21. Karlstrom P, Johansson P, Dahlstrom U, Boman K, Alehagen U. The impact of time to heart failure diagnosis on outcomes in patients tai- lored for heart failure treatment by use of natriuretic peptides. Results from the UPSTEP study. Int J Cardiol. 2017;236:315-320.
  22. Bettencourt P, Frioes F, Azevedo A, et al. Prognostic information pro- vided by serial measurements of brain natriuretic peptide in heart fail- ure. Int J Cardiol. 2004;93(1):45-48.
  23. Jhund PS, Anand IS, Komajda M, et al. Changes in N-terminal pro-B- type natriuretic peptide levels and outcomes in heart failure with pre- served ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015;17(8):809-817.
  24. Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M. Clinical rel- evance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med. 2006;44(4):366- 378.